These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21843063)

  • 1. A hub for bench-to-bedside pharmacogenomic-based research.
    Voora D; Ginsburg GS
    Pharmacogenomics; 2011 Aug; 12(8):1095-8. PubMed ID: 21843063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Institutional profile: integrated center for research and treatment of vertigo, balance and ocular motor disorders.
    Brandt T; Zwergal A; Jahn K; Strupp M
    Restor Neurol Neurosci; 2010; 28(1):135-43. PubMed ID: 20086290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Translational approach for pharmacogenomics and personalized medicine].
    Zhang W; Zhou HH
    Yao Xue Xue Bao; 2011 Jan; 46(1):1-5. PubMed ID: 21465801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Planning for a national effort to enable and accelerate discoveries in pharmacogenetics: the NIH Pharmacogenetics Research Network.
    Long RM
    Clin Pharmacol Ther; 2007 Mar; 81(3):450-4. PubMed ID: 17339874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethics and policy perspectives on personalized medicine in the post-genomic era.
    Landon MR
    J Biolaw Bus; 2005; 8(3):28-36. PubMed ID: 16459425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NIPTE: a multi-university partnership supporting academic drug development.
    Gurvich VJ; Byrn SR
    Drug Discov Today; 2013 Oct; 18(19-20):916-21. PubMed ID: 23732177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Institutional profile: The Carney Centre for Pharmacogenomics: a New Zealand focus for personalized medicine research.
    Kennedy MA; Joyce PR; Begg EJ
    Pharmacogenomics; 2012 Jun; 13(8):865-8. PubMed ID: 22676191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAM evaluation comes into the mainstream: NIH specialized Centers of research and the University of Maryland Center for Alternative Medicine Research in Arthritis.
    Berman BM; Hartnoll S; Bausell B
    Complement Ther Med; 2000 Jun; 8(2):119-22. PubMed ID: 10859605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAVAGATE: a rubric to move from pharmacogenomics science to pharmacogenomics practice.
    Roederer MW
    Pharmacogenomics; 2012 Aug; 13(11):1307-13. PubMed ID: 22920399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Institutional profile: the Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre at the Montreal Heart Institute.
    Dubé MP; Tardif JC
    Pharmacogenomics; 2013 Jan; 14(2):131-6. PubMed ID: 23327574
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacogenomics and public health: implementing 'populationalized' medicine.
    Mette L; Mitropoulos K; Vozikis A; Patrinos GP
    Pharmacogenomics; 2012 May; 13(7):803-13. PubMed ID: 22594512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Institutional profile: the Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK.
    Alfirevic A; Carr DF; Miyajima F; Pushpakom S; Sutton L; Jorgensen AL; Pirmohamed M
    Pharmacogenomics; 2013 Jun; 14(8):861-7. PubMed ID: 23746181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care.
    Rakhra-Burris TK; Auman JT; Deverka P; Dressler LG; Evans JP; Goldberg RM; Havener TM; Hoskins JM; Jonas DE; Long KM; Motsinger-Reif AA; Irvin WJ; Richards KL; Roederer MW; Valgus JM; Riper Mv; Vernon JA; Zamboni WC; Wagner MJ; Walko CM; Weck KE; Wiltshire T; McLeod HL
    Pharmacogenomics; 2010 Jan; 11(1):13-21. PubMed ID: 20017668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomic biomarkers for personalized medicine.
    Chen JJ; Lin WJ; Chen HC
    Pharmacogenomics; 2013 Jun; 14(8):969-80. PubMed ID: 23746190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Company profile: PGXIS Ltd.
    McCarthy A
    Pharmacogenomics; 2011 Sep; 12(9):1253-6. PubMed ID: 21919604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspective: Transforming science into medicine: how clinician-scientists can build bridges across research's "valley of death".
    Roberts SF; Fischhoff MA; Sakowski SA; Feldman EL
    Acad Med; 2012 Mar; 87(3):266-70. PubMed ID: 22373616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics of adverse drug reactions: implementing personalized medicine.
    Wei CY; Lee MT; Chen YT
    Hum Mol Genet; 2012 Oct; 21(R1):R58-65. PubMed ID: 22907657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized medicine: progress and promise.
    Chan IS; Ginsburg GS
    Annu Rev Genomics Hum Genet; 2011; 12():217-44. PubMed ID: 21721939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacogenomics: hype or hope?].
    Schwab M; Schaeffeler E; Zanger UM; Brauch H; Kroemer HK
    Dtsch Med Wochenschr; 2011 Mar; 136(10):461-7. PubMed ID: 21365522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.